| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/23/2002 | US20020061589 Method of immunotherapy; obtain electrodes, obtain waveform generator, generate electrically conductive pathways between electrodes and generator, incubate with transfer particles, transfer particles into cells with electrical pulse |
| 05/23/2002 | US20020061585 Ribozymal nucleic acid |
| 05/23/2002 | US20020061575 27803, a novel human adenylate kinase family member and uses therefor |
| 05/23/2002 | US20020061573 Nucleotide seqences which code enzymatic polypeptide for use in diagnosis and treatment of cell propagation defects, pain, eating, urogenital and brain disorders, cachexia and diabetes |
| 05/23/2002 | US20020061569 Nuclelotide sequences for use in the prevention of proliferation of microorganisms |
| 05/23/2002 | US20020061562 Nucleotide sequences coding enzymatic polypeptide for use in trestment of vision defects |
| 05/23/2002 | US20020061553 Partners of the PTB1 domain of FE65, preparation and uses |
| 05/23/2002 | US20020061551 Nucleotide sequences coding a regulatory protein for use in the treatment of tumors, arteriosclerosis, autoimmune and diseases, blood disorders, asthma, arthritis and leukemia |
| 05/23/2002 | US20020061545 Streptococcus pneumoniae antigens and vaccines |
| 05/23/2002 | US20020061535 Monitoring sample for preferential particles; obtain sample, incubate on test column, wash column, incubate with probes, wash column, detect signals |
| 05/23/2002 | US20020061527 Human DNA topoisomerase I alpha |
| 05/23/2002 | US20020061525 Sequences of trail variants |
| 05/23/2002 | US20020061521 Nucleic acids, proteins, and antibodies |
| 05/23/2002 | US20020061517 Adenovirus carrying gag gene HIV vaccine |
| 05/23/2002 | US20020061336 Also comprising a hydrogel, for use in the treatment of a subject by particle injection |
| 05/23/2002 | US20020061299 Protecting tissues from ischemia/reperfusion injury via introducing/ expressing gene construct encoding thereapeutic antioxidant |
| 05/23/2002 | US20020061297 Novel recombinant DNA vectors for gene therapy |
| 05/23/2002 | US20020061295 Myocardial grafts and cellular compositions useful for same |
| 05/23/2002 | US20020061294 Mononuclear phagocytes in therapeutic drug delivery |
| 05/23/2002 | US20020061293 Transduced human hematopoietic stem cells |
| 05/23/2002 | US20020061287 Process of making a compound by forming a polymer from a template drug |
| 05/23/2002 | DE10057443A1 Use of specific antibodies, or individual chains, for treating tumors and vascular occlusions, by inhibition of the gpIIb/IIIa receptor |
| 05/23/2002 | CA2429897A1 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | CA2429894A1 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | CA2429460A1 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | CA2429342A1 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/23/2002 | CA2428754A1 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | CA2427902A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 05/23/2002 | CA2427896A1 Carrier vectors through an epithelium with tight junctions |
| 05/23/2002 | CA2420983A1 Molecules for disease detection and treatment |
| 05/22/2002 | EP1207205A1 Adenoviral replicons |
| 05/22/2002 | EP1207200A1 High affinity choline transporter |
| 05/22/2002 | EP1206576A1 Novel kinases and uses thereof |
| 05/22/2002 | EP1206574A2 Guanidinium functionalized oligomers and methods |
| 05/22/2002 | EP1206563A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 05/22/2002 | EP1206553A2 Isomerase proteins |
| 05/22/2002 | EP1206549A1 Basb119 polypeptide and polynucleotide from moraxella catarrhalis |
| 05/22/2002 | EP1206548A1 Basb118 polypeptide and polynucleotide from moraxella catarrhalis |
| 05/22/2002 | EP1206545A1 Basb116 dna and proteins from moraxella catarrhalis |
| 05/22/2002 | EP1206544A2 Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof |
| 05/22/2002 | EP1206542A2 Replication protein a binding transcriptional factor (rbt1) and uses thereof |
| 05/22/2002 | EP1206541A1 Dendritic enriched secreted lymphocyte activation molecule |
| 05/22/2002 | EP1206539A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 05/22/2002 | EP1206535A1 Tumor-associated antigen (r11) |
| 05/22/2002 | EP1206529A2 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-BETA 1,3-N-ACETYLGALACTOSAMINE-ALPHA-R/(GlcNAc to GalNAc) BETA 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 05/22/2002 | EP1206527A1 Treatment of inflammatory or malignant disease using dnazymes |
| 05/22/2002 | EP1206525A2 Method for growing stem cells |
| 05/22/2002 | EP1206491A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 05/22/2002 | EP1206487A2 Notch receptor ligands and uses thereof |
| 05/22/2002 | EP1206478A1 Antisense modulation of mekk5 expression |
| 05/22/2002 | EP1206285A2 Drug-carrier complexes and methods of use thereof |
| 05/22/2002 | EP1206284A1 Method for delivery of therapeutic agents using a solution of dextrin |
| 05/22/2002 | EP1206233A2 Serine proteases |
| 05/22/2002 | EP1049487B1 Treatment of acute intermittent porphyria (aip) and other porphyric diseases |
| 05/22/2002 | EP0981648A4 ANTISENSE INHIBITION OF ras GENE WITH CHIMERIC AND ALTERNATING OLIGONUCLEOTIDES |
| 05/22/2002 | CN1350592A Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 05/22/2002 | CN1350585A i(Neisseria meningitidis) polypeptide BASBO52 |
| 05/22/2002 | CN1350578A Recombinant influenza viruses for vaccines and gene therapy |
| 05/22/2002 | CN1350546A 结核诊断测验 TB diagnostic test |
| 05/22/2002 | CN1350542A Xylo-LNA analogues |
| 05/21/2002 | US6392118 Stable cultures; for controlling cell distribution within artificial organ |
| 05/21/2002 | US6392069 Compositions for enhancing delivery of nucleic acids to cells |
| 05/21/2002 | US6392028 Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| 05/21/2002 | US6392016 Preferential polypeptide for use in the diagnosis and treatment of tumors; antiproliferative agents |
| 05/21/2002 | US6391858 Gene delivery in various muscle cell types; gene therapy for expression of erythropoietin to treat blood disorders such as anemias, for example |
| 05/21/2002 | US6391853 Human tissue inhibitor of metalloproteinase-4 |
| 05/21/2002 | US6391850 Methods and compositions for inhibiting angiogenesis |
| 05/21/2002 | US6391632 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| 05/21/2002 | US6391631 Nucleotide sequences for use as tools in genetic engineering and analysis |
| 05/21/2002 | US6391612 Replicating preferential plasmids; obtain nuclelotide sequences, transform cells, allow replication, recover plasmids |
| 05/21/2002 | US6391600 PcrA helicase |
| 05/21/2002 | US6391580 Ras proteins |
| 05/21/2002 | US6391579 Nucleotide sequences coding transport protein for use in the treatment of thyroid defects |
| 05/21/2002 | US6391574 AFC1 and RCE1: isoprenylated CAAX processing enzymes |
| 05/21/2002 | US6391553 Analyzing level of gene expression of epsilon 4 or epsilon 2 alleles of apolipoprotein e; mutation in consensus sequence binding a transcription factor and either increase in epsilon 4 or decrease in epsilon 2 indicate disease |
| 05/21/2002 | US6391314 Immunogenic composition comprising vector that contains and expresses in vivo in porcine host cell, nucleic acid molecule or fragment thereof encoding type ii porcine circovirus antigen and pharmaceutically acceptable vehicle or diluent |
| 05/21/2002 | US6391311 Polypeptide comprising amino acid sequence at least about 80% identical to specified sequence, which has biological activity of promoting selective growth and/or survival of human umbilical vein endothelial cells in in vitro assay |
| 05/21/2002 | US6391298 Method of using PON-1 to decrease atheroma formation |
| 05/21/2002 | US6391297 Differentiation of adipose stromal cells into osteoblasts and uses thereof |
| 05/21/2002 | US6390821 Phosphorylation |
| 05/20/2002 | WO2002039947A2 Carrier vectors through an epithelium with tight junctions |
| 05/16/2002 | WO2002039116A2 Retrovirus isolated from humans |
| 05/16/2002 | WO2002038797A2 Modulators of bruton's tyrosine kinase, their identification and use |
| 05/16/2002 | WO2002038782A2 Viral expression system |
| 05/16/2002 | WO2002038781A1 Use of heart-specific transcription factors of the basic helix-loop-helix type for treating cardiac power failure |
| 05/16/2002 | WO2002038776A1 Regulation of human fatty acid coa ligase |
| 05/16/2002 | WO2002038775A2 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE |
| 05/16/2002 | WO2002038773A2 A human phospholipase c and uses thereof |
| 05/16/2002 | WO2002038767A2 G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| 05/16/2002 | WO2002038752A2 Use of a helminth for the in vivo delivery of a medicament |
| 05/16/2002 | WO2002038741A1 Cell reprogramming |
| 05/16/2002 | WO2002038738A2 Chimeric molecules to modulate gene expression |
| 05/16/2002 | WO2002038726A2 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 05/16/2002 | WO2002038609A2 Apolipoprotein conjugates |
| 05/16/2002 | WO2002038601A2 Foggy |
| 05/16/2002 | WO2002038600A2 C. elegans genes involved in viability and/or reproduction and uses thereof |
| 05/16/2002 | WO2002038188A2 Use of the human lrp/mvp promotor for a vector that can be induced by therapy |
| 05/16/2002 | WO2002038173A1 Vaccine based on a cellular penetration factor from an apicomplexan parasite |
| 05/16/2002 | WO2002038171A2 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 05/16/2002 | WO2002038169A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |